CONTACT
+91 80 2808 2808
info@biocon.com

News - Posts

Biocon  /  News – Posts

U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon’s Proposed Biosimilar Trastuzumab

  • Posted by: BIOCON

Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon’s Proposed Biosimilar Trastuzumab Phase 3 Data

  • Posted by: BIOCON

Biocon Features in Asia IP Elite 2016 List

  • Posted by: BIOCON

Biocon’s Novel Diabetes Education Initiative for Medical Practitioners ‘ABIDE’ Awarded by RSSDI

  • Posted by: BIOCON

Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management Across India

  • Posted by: BIOCON

Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab

  • Posted by: BIOCON

Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European Medicines Agency

  • Posted by: BIOCON

Biocon Ranked Among Global Top Ten Biotech Employers; The only Asian Company to Feature in 2016 Rankings Biocon moves up to No. 9 from No. 13 last year

  • Posted by: BIOCON

Biocon Q2 FY17 Revenue Up 21%; EBITDA Up 45%; Revenues at Rs 992 Crs.; EBITDA at Rs 277 Crs.; Net Profit at Rs 147 Crs.

  • Posted by: BIOCON

Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business

  • Posted by: BIOCON
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>